19 patients with primary open angle glaucoma (POAG) refractory to topical medical therapy were operated in late 2020 and a novel interposition supraciliary device implanted.~These patients reached 6 months follow-up and the original study had to be interrupted.~This observational study prolonges follow-up to 36 months
The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.